Salarius Pharmaceuticals (SLRX) Stock Overview

Focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. More details

SLRX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($4M)

Shareholders have been substantially diluted in the past year

+ 1 more risk

SLRX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Salarius Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Salarius Pharmaceuticals
Historical stock prices
Current Share Price	US$0.66
52 Week High	US$108.00
52 Week Low	US$0.62
Beta	0.40
1 Month Change	-30.07%
3 Month Change	-82.70%
1 Year Change	-97.38%
3 Year Change	-99.64%
5 Year Change	-99.98%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	SLRX	US Biotechs	US Market
7D	-4.1%	1.1%	1.3%
1Y	-97.4%	26.4%	15.8%

Return vs Industry: SLRX underperformed the US Biotechs industry which returned 26.4% over the past year.

Return vs Market: SLRX underperformed the US Market which returned 15.8% over the past year.

Price Volatility

Is SLRX's price volatile compared to industry and market?
SLRX volatility
SLRX Average Weekly Movement	21.4%
Biotechs Industry Average Movement	11.3%
Market Average Movement	6.4%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	2.9%

Stable Share Price: SLRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SLRX's weekly volatility has decreased from 28% to 21% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	2	Rick Pierce	www.salariuspharma.com

Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.

Salarius Pharmaceuticals, Inc. Fundamentals Summary

How do Salarius Pharmaceuticals's earnings and revenue compare to its market cap?
SLRX fundamental statistics
Market cap	US$3.85m
Earnings (TTM)	-US$5.00m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Is SLRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLRX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$5.00m
Earnings	-US$5.00m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.85
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SLRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/28 02:47
End of Day Share Price	2025/12/26 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Salarius Pharmaceuticals, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Aydin Huseynov	Benchmark Company
Michael King	H.C. Wainwright & Co.